265 completed, 98 unknown, 88 terminated, 72 recruiting. 611 Phase 2, 160 Phase 1, 7 Phase 3.
Follow Lymphoma, T-Cell: new trials by email Literature Review of Lymphoma, T-Cell trials Research Report on Lymphoma, T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma Stapokibart, immune checkpoint inhibitor - Lymphoma, NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2026-12-01 | 2026-08-28 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Allogeneic Cell Therapy in Refractory T-Cell Lymphoma Baseline FDG-PET/CT, First-line chemotherapy, Interim FDG-PET/CT after two cycles of first-line chemotherapy - Lymphoma, T Cell, Peripheral | Phase 2 | Not yet recruiting | University Medical Center Goettingen | 70 | 2026-11-01 | 2026-11-05 |
| A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma Zeprumetostat Tablets - Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome | Phase 2 | Not yet recruiting | Peking University First Hospital | 33 | 2026-10-31 | 2026-10-02 |
| Topical JAK-Inhibition of Early-Stage CTCL delgocitinib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 2 | Not yet recruiting | Aarhus University Hospital | 15 | 2026-09-01 | 2026-08-26 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 25 | 2026-08-03 | 2026-10-19 |
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma Benvitimod Cream, Placebo cream - Cutaneous T-Cell Lymphoma, Mycosis Fungoides (MF) | Phase 2 | Not yet recruiting | Peking University First Hospital | 35 | 2026-07-01 | 2026-06-22 |
| Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma Adebrelimab & SHR2554 - Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2026-05-29 | 2026-05-29 |
| Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin - Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 34 | 2026-05-15 | 2026-04-28 |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides A-dmDT390-bisFv(UCHT1), Vorinostat - Mycosis Fungoides | Phase 2 | Withdrawn | Virogen Biotechnology Inc. | 2026-05-01 | 2026-05-18 | |
| Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma Tislelizumab, Zeprumetostat - Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Rong Tao | 107 | 2026-04-30 | 2026-06-18 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) GW5282 combined with Golidocitinib, Conventional CHOP regimen - T-cell Lymphomas | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2026-04-15 | 2026-10-22 |
| Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase - Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 25 | 2026-04-01 | 2026-04-13 |
Showing 20 of 611. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (203) · Lymphoma, T-Cell, Peripheral (188) · Mycosis Fungoides (164) · Lymphoma (163) · Lymphoma, Large-Cell, Anaplastic (152) · Lymphoma, Large B-Cell, Diffuse (145) · Lymphoma, Non-Hodgkin (143) · Sezary Syndrome (128) · Lymphoma, Extranodal NK-T-Cell (126) · Hodgkin Disease (122) · Lymphoma, Follicular (122) · Lymphoma, Mantle-Cell (119) · Leukemia, Lymphocytic, Chronic, B-Cell (110) · Burkitt Lymphoma (109)
Neoplasms by Histologic Type (607) · Neoplasms (596) · Hemic and Lymphatic Diseases (561) · Lymphatic Diseases (557) · Immunoproliferative Disorders (554) · Immune System Diseases (552) · Lymphoproliferative Disorders (543) · Lymphoma, Non-Hodgkin (468) · Lymphoma (448) · Hematologic Diseases (167) · Pathological Conditions, Signs and Symptoms (164) · Pathologic Processes (162) · Disease Attributes (158) · Leukemia, Lymphoid (157)
Cyclophosphamide (89) · Etoposide (57) · fludarabine phosphate (41) · Prednisone (40) · Peripheral Blood Stem Cell Transplantation (39) · Doxorubicin (36) · Mycophenolic Acid (35) · Vincristine (35) · Brentuximab Vedotin (33) · Whole-Body Irradiation (33) · Gemcitabine (31) · Busulfan (30) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (29) · Rituximab (29) · Tacrolimus (28)
National Cancer Institute (NCI) (32) · Fred Hutchinson Cancer Center (29) · M.D. Anderson Cancer Center (21) · Sun Yat-sen University (17) · Ruijin Hospital (14) · Memorial Sloan Kettering Cancer Center (13) · Northwestern University (12) · City of Hope Medical Center (10) · European Organisation for Research and Treatment of Cancer - EORTC (9) · Fudan University (9) · Mayo Clinic (9) · Peking Union Medical College Hospital (8) · Samsung Medical Center (8) · Seagen Inc. (8) · Beijing Tongren Hospital (7)
United States (343) · China (130) · France (55) · Italy (41) · United Kingdom (37) · Germany (31) · Spain (30) · South Korea (29) · Canada (23) · Australia (18) · Belgium (18) · Japan (14) · Netherlands (10) · Poland (9) · Switzerland (9)
Timothy M. Kuzel, MD (5) · Ajay Gopal (4) · Brenda Sandmaier (4) · Madeleine Duvic, MD (4) · David J. Straus, MD (3) · Liang Wang (3) · Steven M. Horwitz, MD (3) · Wenqi Jiang, MD (3) · Won Seog Kim, MD, PhD (3) · Ye Guo, MD (3) · Adam Lerner, MD (2)
PMID 32632956, PMID 32499241, PMID 17242396, PMID 22045986, PMID 24652992, PMID 25795722, PMID 28974506, PMID 31029646, PMID 34702811, PMID 35536441, PMID 35882475, PMID 39821757, PMID 12097283, PMID 1244564, PMID 12543862, PMID 14630682, PMID 14739217, PMID 15107815, PMID 15386331, PMID 16731764, PMID 16966261, PMID 17366595, PMID 17515522, PMID 17515574, PMID 18079362, PMID 18327587, PMID 18596230, PMID 18645136, PMID 19170225, PMID 19199905, PMID 19466965, PMID 19536896, PMID 19597183, PMID 19789316, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20697067, PMID 20697094, PMID 20888065, PMID 20942843, PMID 21123825, PMID 21135857, PMID 21270441, PMID 21355097, PMID 21504290, PMID 21576639
P30CA015704 (15), 2023 (7), P30CA033572 (7), P30CA036727 (6), P30CA015083 (5), 2018 (4), P01CA018029 (4), U10CA032102 (4), 2008 (3), 2016 (3), 2017 (3), N01CM62202 (3), P30CA008748 (3), P30CA016672 (3), P30CA043703 (3)